Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini oral session - Public policy

1510MO_PR - European cancer patients’ perspectives on Immunotherapy

Date

18 Sep 2021

Session

Mini oral session - Public policy

Presenters

Paraskevas Kosmidis

Citation

Annals of Oncology (2021) 32 (suppl_5): S1102-S1110. 10.1016/annonc/annonc711

Authors

P. Kosmidis, C. Lagogianni, T. Kosmidis

Author affiliations

  • R&d, Care Across Ltd, N21 3NA - London/GB
More

Resources

Login to access the resources on OncologyPRO.

Abstract 1510MO_PR

Background

Despite the efforts of scientific organisations, patients’ views of immunotherapy are unclear. CareAcross, a multilingual digital platform which provides personalised, evidence-based support to cancer patients, investigated their views on immunotherapy.

Methods

In the second half of 2020, members of the CareAcross platforms (primarily from the UK, France, Spain, Italy or Germany) responded to relevant questions.

Results

Among 5589 patients who responded, 4064 had breast (BC), 1131 lung (LC), 231 prostate (PC) and 163 colorectal cancer (CC). When asked “How does immunotherapy work?”, 55% of BC, 34% of LC, 60% of PC and 45% of CC responded either “Not Sure” or “Do Not Know”. Regarding its timing of action, most (50-61%) responded “Do Not Know”. Responses to these 2 questions are detailed below: Table: 1510MO

1510MO

Breast Lung Prostate Colorectal
N (Σ=5589) 4064 1131 231 163
Q: How does Immunotherapy work?
Helps our immune system 11% 13% 8% 9%
Stops cancer cells from affecting our immune system 7% 4% 2% 3%
Activates our immune system to kill cancer cells 29% 41% 34% 42%
Attacks cancer cells like our immune system 7% 7% 6% 5%
Turns cancer cells into immune system cells 1% 1% 0% 1%
Not sure/Do not know 45% 34% 50% 40%
Q: When does it work?
Starts as soon as treatment begins 17% 18% 10% 13%
Starts some time after treatment begins 18% 25% 21% 18%
Stops when treatment completes 2% 1% 0% 1%
Continues after treatment completes 18% 14% 18% 11%
Do not know 52% 50% 56% 61%

When comparing immunotherapy’s side-effects with chemotherapy’s, 24% of BC, 23% of LC, 31% of PC and 34% of CC responded “Do Not Know”. Most (60-74%) perceived chemotherapy as more toxic; very few considered immunotherapy more toxic (2-5%). Compared to targeted therapy, most (58-65%) did not know. 21-26% believed targeted therapy is more toxic, and few that immunotherapy is more toxic (9-15%). Regarding costs to the healthcare system, patients were asked to compare immunotherapy, chemotherapy and targeted therapy. Most did not know (53-58%), while BC and PC patients believe that chemotherapy costs the most. Chemotherapy, immunotherapy and targeted therapy were selected as the most expensive by 23%, 11%, 6% (BC); 12%, 17%, 12% (LC); 25%, 10%, 8% (PC); and 11%, 17%, 12% (CC), respectively. Among LC patients, those receiving immunotherapy (241 of 1131) had as much as twice the correct answer percentages, except side-effects (they perceived it more toxic compared to LC patients not receiving it).

Conclusions

Most patients do not know enough about immunotherapy, its mechanism and timing of action, and its costs to the healthcare system. Among 4 cancer types, lung cancer patients (especially those treated with immunotherapy) are better informed.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Care Across Ltd.

Funding

Care Across Ltd.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings